Indivior (LON:INDV)‘s stock had its “outperform” rating reissued by Royal Bank of Canada in a note issued to investors on Friday. They currently have a GBX 350 ($4.57) price objective on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 73.01% from the stock’s current price.
Other analysts have also recently issued reports about the company. Jefferies Financial Group cut their price objective on Indivior from GBX 250 ($3.27) to GBX 245 ($3.20) and set a “buy” rating for the company in a research report on Thursday, October 11th. Numis Securities restated a “buy” rating and issued a GBX 350 ($4.57) price objective on shares of Indivior in a research report on Thursday, September 27th. Finally, Citigroup restated a “neutral” rating on shares of Indivior in a research report on Monday, October 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of GBX 338.60 ($4.42).
Shares of Indivior stock traded up GBX 10.20 ($0.13) on Friday, reaching GBX 202.30 ($2.64). The company’s stock had a trading volume of 5,082,049 shares, compared to its average volume of 2,440,000. Indivior has a 52-week low of GBX 246.50 ($3.22) and a 52-week high of GBX 436.60 ($5.70).
Indivior Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.